Anti-cancer gold(I) phosphine complexes: Cyclic trimers and tetramers containing the P-Au-P moiety.

We report the application of cationic tri- and tetra-nuclear gold(I) phosphine complexes [Au3(µ-dppen)3]X3 and [Au4(µ-dppa)4]X4 (X=OTf, PF6) [OTf=trifluoromethanesulfonate, dppen=trans-1,2-bis(diphenylphosphino)ethene, dppa=bis(diphenylphosphino)acetylene] for cancer treatment. The results of cytotoxicity tests on four different cancer cells [prostate (DU145), cervical (HeLa), breast (MDAMB-231) and fibro sarcoma (HT1080)] indicate these complexes possess remarkable tumor cell growth inhibitory effects and high selectivity towards cancer cells. The anti-tumor mechanism of the tri- and tetra-nuclear gold(I) complexes has also been investigated.

Human Serum Albumin-Delivered [Au(PEt3)]+ Is a Potent Inhibitor of T Cell Proliferation.

Using a modular library format in conjunction with cell viability (MTS) and flow cytometry assays, 90 cationic complexes [AuPL] n+ (P = phosphine ligand; L = thiourea derivative or chloride) were studied for their antiproliferative activity in CD8+ T lymphocyte cells. The activity of the compounds correlates with the steric bulk of the phosphine ligands. Thiourea serves as a leaving group that is readily replaced by cysteine thiol (NMR, ESI-MS). Taking advantage of selective thiourea ligand exchange, the fragments [Au(PEt3)]+ and [Au(JohnPhos)]+ (JohnPhos = 1,1'-biphenyl-2-yl)di-tert-butylphosphine) in compounds 1 and 2 were transferred to recombinant human serum albumin (rHSA). PEt3 promoted efficient modification of Cys34 in HSA (HSA-1), whereas use of bulky JohnPhos as a carrier ligand led to serum protein nonspecifically modified with multiple gold adducts (HSA-2) (Ellman's test, ESI-TOF MS). HSA-1, but not HSA-2, strongly inhibits T cell proliferation at nanomolar doses. The potential role of HSA as a delivery vehicle in gold-based autoimmune disease treatment is discussed.